trial summary · NCT07578116
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
Trial record from the TrialBase DB dataset, status RECRUITING, condition Anatomic Stage IV Breast Cancer AJCC v8, sponsored by SWOG Cancer Research Network. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body …
Source record: https://clinicaltrials.gov/study/NCT07578116
Facts
| registry id | NCT07578116 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Anatomic Stage IV Breast Cancer AJCC v8 |
| sponsor | SWOG Cancer Research Network |
| sponsor class | NETWORK |
| enrollment | 562 |
| start date | 2027-03-09 |
| primary completion | 2032-05-31 |
| completion | 2033-05-31 |
| results posted | not reported |
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic HER2-Positive Breast Carcinoma
- Oligometastatic Breast Carcinoma
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Breast Conservation Treatment
- Computed Tomography
- Cyclin-Dependent Kinase 4 Inhibitor
- Cyclin-Dependent Kinase 6 Inhibitor
- Echocardiography Test
- HER2-targeted Therapy
- Hormone Therapy
- Magnetic Resonance Imaging
- Mammography
- Pertuzumab
11 more in the dataset.
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, PROCEDURE, RADIATION
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.